Harmony Biosciences Holdings Q3 2026 earnings

HRMY · 2026-11-04 08:00 BMO ET · 8-K on SEC · 10-Q on SEC

WAKIX revenue grew 12% YoY to $269M, but net income fell 5% YoY to $48.2M due to milestone and MSN royalty charges.

Headline numbers

MetricActualYoYQoQ8-K location
Revenue$268.9M+12%+2.9%Ex. 99.1, income statement
EPS (GAAP)$0.81-7%-36.7%Ex. 99.1, income statement
Net income$48.2M-5%-36.1%Ex. 99.1, income statement
Adj. EBITDA$71.5M+31%-19.9%Ex. 99.1, income statement
Adj. EBITDA margin26.6%+4.4 pp-3.6 ppEx. 99.1, income statement

Revenue breakdown

SegmentActualYoYShare of revenueNote
WAKIX (pitolisant)$268.9M+12%100%Net product revenue

Margins and costs

  • Gross margin 70.0% (prior 75.0%, change -5.0 pp)
  • Operating expenses $134.0M (+17.3% YoY)
  • One-offs in the quarter Milestone charges; MSN royalty charges
  • Effective tax rate 18.7% (prior-year 24.7%, year-to-date 18.8%)
  • Non-GAAP bridge Adds back interest expense, interest income, unrealized loss on investments, income tax expense, and other expense, net. Milestone and MSN royalty charges are recurring.

KPIs

MetricActualPrior quarterPrior yearChange
Average patients9,3508,9508,500+400
Cash, cash equivalents and investments$1,051.6M$962.5M$882.5M+$89.1M

Guidance

MetricGuidePrior guideChange
WAKIX Net Revenue$1.0B - $1.04B$1.0B - $1.04BNo change

What drove it

  • Revenue story WAKIX net revenue grew 12% YoY to $268.9M, driven by 400 net patient adds.
  • EPS story EPS declined YoY due to higher milestone and MSN royalty charges.
  • One-off check Milestone charges and MSN royalty charges totaling $2.5M (approx) and $3.0M (approx) respectively.

The good

  • WAKIX revenue growth of 12% YoY
  • Cash balance of $1,051.6M

The bad

  • Net income declined 5% YoY
  • Cost of product sold increased to 30% of revenue

The ugly

  • none

Open questions

  • The filing mentions 'MSN royalty charges' but does not quantify the exact amount.
  • The filing mentions 'milestone charges' but does not quantify the exact amount.
Full release

Harmony Biosciences Holdings (HRMY) earnings release, November 4, 2026

Harmony Biosciences Holdings, Inc. (HRMY) · Form 8-K, Item 2.02 · Filed · SEC filing

‌

Harmony Biosciences Reports Q3 Financial Results

On Track to Achieve More Than $1 Billion WAKIX Net

Revenue and Announces Strong Multiple-Ascending Dose Data for Its Orexin Agonist BP-205, Supporting Potential Best-in-Class Profile

​

WAKIX ® Net Revenue in Q3 of $269 Million; Driven by Strong Demand with 400 Net Patient Adds in the Quarter; Reiterates Full Year Guidance of $1.0B to $1.04B

​

Repeated Once-Daily Dosing with BP-205 in Multiple-Ascending Dose Study Reinforces Favorable Safety, Tolerability and Pharmacokinetic Profile Observed in Single-Ascending Dose Study

​

Results from Phase 1b Study in Sleep-Deprived Healthy Volunteers for BP-205 Remain on Track for Q1 2027; Phase 2 Studies in Multiple CNS Indications Expected to Initiate by Mid-2027

​

Pitolisant GR NDA Under FDA Review, PDUFA Date April 1, 2027; Pitolisant HD Phase 3 Topline Data in 2027, Target PDUFA Date in 2028

​

Multi-Layered IP Strategy Across Active Legal Proceedings Reinforces Confidence in WAKIX Exclusivity to March 2030

​

Peter Anastasiou to Succeed Jeffrey Dayno, MD, as President and Chief Executive Officer Effective January 1, 2027

​

Conference Call and Webcast Today at 8:30 a.m. ET

​

PLYMOUTH MEETING, Pa., November 4, 2026 /Globe Newswire/

-- Harmony Biosciences Holdings, Inc. (Nasdaq: HRMY), today reported third quarter 2026 financial results and preliminary data from its multiple-ascending dose (MAD) clinical study for its potential best-in-class orexin agonist BP-205. WAKIX® (pitolisant) delivered third quarter net revenue of $269 million, driven by strong demand of 400 net patient adds, and the Company remains on track to achieve full-year WAKIX net revenue guidance of $1.0 billion to $1.04 billion.

​

​

​

The encouraging preliminary results from the MAD study with BP-205, following 14 days of repeated once-daily dosing, reinforce the favorable safety, tolerability and pharmacokinetic profile observed in the single-ascending dose (SAD) portion of the study. No liver or visual adverse events were reported, and no clinically significant cardiovascular events or EKG abnormalities were recorded. Harmony remains on track to report Phase 1b data in sleep-deprived healthy volunteers in the first quarter of 2027, followed by the initiation of Phase 2 studies across multiple CNS indications by mid-2027.

​

Additionally, as announced on October 12, 2026, Peter Anastasiou, Senior Executive Vice President and Chief Operating Officer, will become President and Chief Executive Officer effective January 1, 2027, succeeding Jeffrey Dayno, MD, who will retire on December 31, 2026. This planned leadership transition does not change Harmony's previously communicated strategic priorities or the expected timing of key commercial and pipeline milestones.

​

“As I prepare to transition the

President and

CEO role to Peter on January 1, I believe Harmony is operating from a position of strength, with a durable and growing WAKIX franchise, the financial flexibility to invest in innovation, conviction to pursue strategic business development opportunities, and a pipeline led by BP-205 that has the potential to generate si gnificant long-term value,” said Jeffrey Dayno, MD, President and Chief Executive Officer of Harmony Biosciences. “

I am proud of the talented team and passionate organization we have built, which position Harmony for continued success in delivering innovative treatments to patients and sustained value for our shareholders.”

​

Key Drivers of Value Creation

​

Continued WAKIX Growth in an Evolving Market

​

Third Quarter 2026 Net Product Revenue for WAKIX

​

​

​

On Track to Achieve 2026 WAKIX Net Revenue Guidance of $1.0 Billion to $1.04 Billion

​

Advance Robust, Self-Funded Pipeline

​

BP-205 (Orexin-2 receptor agonist)

​

BP-205 MAD Study Design and Preliminary Results

​

​

​

Pitolisant GR (gastro-resistant) Tablets: On track to launch in 1H 2027

​

Pitolisant HD (high dose): Opportunity to extend the pitolisant franchise with differentiated labeling

​

WAKIX (pitolisant): Phase 3 trial in Prader-Willi syndrome (PWS) (TEMPO)

​

Exploring amorphous form of pitolisant to pursue broader CNS indications

​

EPX-100 (clemizole hydrochloride)

​

​

​

Emphasis on Business Development

​

​

Protect the Pitolisant Franchise

​

​

​

​

Third Quarter 2026 Financial Results

​

Harmony Biosciences reported WAKIX net revenue of $268.9 million for the quarter ended September 30, 2026, compared to $239.5 million for the quarter ended September 30, 2025, representing a 12% increase over the same period. This performance reflects continued strong demand for WAKIX within the large narcolepsy market opportunity (approximately 80,000 diagnosed patients in the U.S.), disciplined commercial execution across the franchise and the product's broad clinical utility. Based on our results for the first nine months of 2026, WAKIX remains on track to achieve full-year net revenue of $1.0 billion to $1.04 billion.

​

Cost of product sold was $80.7 million in the third quarter of 2026, or 30% as a percentage of WAKIX net revenue, as compared to $59.7 million, or 25%, for the same quarter in 2025, representing a 35% increase. The increase in cost of product sold as a percentage of net product revenue was primarily driven by new royalties related to the Novitium license agreement.

​

Net income for the third quarter was $48.2 million, or $0.81 per diluted share, compared to $50.9 million, or $0.87 per diluted share, for the same quarter in 2025. The decline in earnings was primarily driven by an increase in milestone charges and the new MSN royalty charges during the third quarter of 2026 as compared to the same quarter in 2025.

​

Harmony’s operating expenses include the following:

​

​

​

As of September 30, 2026, Harmony had cash, cash equivalents and investments of $1,051.6 million, compared to $882.5 million as of December 31, 2025.

​... (truncated)iorities

​

2026 WAKIX Net Revenue Guidance

Reiterated full year guidance of $1.0 billion to $1.04 billion.

​

Conference Call Today at 8:30 a.m. ET

Harmony is hosting its third quarter 2026 financial results conference call and webcast today, beginning at 8:30 a.m. Eastern Time. The live and replay webcast of the call will be available on the investor relations page of our website https://ir.harmonybiosciences.com/.

​

To participate in the call, please dial 800-347-6865 (domestic) or 203-518-9757 (international or alternate), and reference passcode HRMYQ326.

​

About Harmony Biosciences

Harmony Biosciences is developing and commercializing innovative medicines for both rare and broad CNS disorders, and we are becoming an enduring leader in neuroscience. Our first medicine, WAKIX® (pitolisant), is the first and only FDA-approved non-scheduled treatment for excessive daytime sleepiness or cataplexy in patients 6 years of age and older with narcolepsy. Its launch ranks among the most successful in the history of orphan drugs. Building on our success and profitability, we are continuing to advance our novel clinical-stage pipeline, led by BP-205, an investigational orexin-2 receptor agonist with best-in-class potential across a broad range of CNS disorders. With a strong balance sheet, we have the capacity and conviction to pursue strategic business development opportunities. Harmony is guided by an unwavering commitment to patients and driven to create long-term value for shareholders. For more information, visit: www.harmonybiosciences.com.

​

Financial statements

Income Statement

Three Months Ended September 30, — (In thousands, except share and per share data)

Three Months Ended September 30, – 2026Three Months Ended September 30, – 2025Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
Net product revenue268,917239,455745,584624,677
Cost of product sold80,68659,650188,396129,797
Gross profit188,231179,805557,188494,880
Operating expenses:
Research and development71,66354,962187,642139,661
Sales and marketing34,72129,549100,53590,333
General and administrative27,65029,80788,20794,974
Total operating expenses134,034114,318376,384324,968
Operating income54,19765,487180,804169,912
Other expense, net-316-106-496-575
Interest expense-3,060-3,621-9,364-11,103
Interest income8,4285,73021,25716,070
Income before income taxes59,24967,490192,201174,304
Income tax expense-11,053-16,625-36,086-38,103
Net income48,19650,865156,115136,201
Unrealized (loss) income on investments-1,213118-2,286291
Comprehensive income46,98350,983153,829136,492
EARNINGS PER SHARE:
Basic0.830.882.682.36
Diluted0.810.872.632.32
Weighted average number of shares of common stock - basic58,409,88057,550,90258,271,50957,655,272
Weighted average number of shares of common stock - diluted59,679,31958,717,91059,272,60258,738,361

Balance Sheet

September 30, — (In thousands, except share and per share data)

September 30, – 2026December 31, – 2025
CURRENT ASSETS:
Cash and cash equivalents647,099752,502
Investments, short-term124,03922,838
Trade receivables, net127,73996,787
Inventory, net5,8715,357
Prepaid expenses18,10116,014
Other current assets11,98113,516
Total current assets934,830907,014
NONCURRENT ASSETS:
Investments, long-term280,467107,127
Intangible assets, net71,53589,418
Deferred tax asset161,365149,699
Other noncurrent assets30,04818,373
Total noncurrent assets543,415364,617
TOTAL ASSETS1,478,2451,271,631
CURRENT LIABILITIES:
Trade payables26,91917,693
Accrued compensation14,88618,443
Accrued expenses208,062191,039
Current portion of long-term debt20,00020,000
Other current liabilities1,6754,957
Total current liabilities271,542252,132
NONCURRENT LIABILITIES:
Long-term debt, net129,104143,663
Other noncurrent liabilities5,3675,618
Total noncurrent liabilities134,471149,281
TOTAL LIABILITIES406,013401,413
STOCKHOLDERS’ EQUITY:
Common stock—$0.00001 par value; 500,000,000 shares authorized at September 30, 2026 and December 31, 2025, respectively; 58,720,081 and 57,726,170 shares issued and outstanding at September 30, 2026, and December 31, 2025, respectively11
Additional paid in capital757,153708,968
Accumulated other comprehensive (loss) income-1,940346
Retained earnings317,018160,903
TOTAL STOCKHOLDERS’ EQUITY1,072,232870,218
TOTAL LIABILITIES AND STOCKHOLDERS’ EQUITY1,478,2451,271,631

Cash Flow

From the 10-Q · Nine Months Ended September 30, — (In thousands, except share and per share data)

Nine Months Ended September 30, – 2026Nine Months Ended September 30, – 2025
CASH FLOWS FROM OPERATING ACTIVITIES
Net income156,115136,201
Adjustments to reconcile net income to net cash used in operating activities:
Depreciation2120
Intangible amortization17,88317,883
Acquired in-process research & development (IPR&D) expense57,00030,000
Stock-based compensation28,00134,923
Stock appreciation rights market adjustment13-255
Debt issuance costs amortization441490
Deferred taxes-11,666-14,677
Amortization of premiums and accretion of discounts on investment securities-1,352-1,240
Other non-cash expenses1,769923
Change in operating assets and liabilities:
Trade receivables-30,952-17,618
Inventory-514316
Prepaid expenses and other assets-12,3796,942
Trade payables9,22612,597
Other liabilities-16,72115,543

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. All statements contained in this press release that do not relate to matters of historical fact should be considered forward-looking statements, including statements regarding our full year 2026 net product revenue, expectations for the growth and value of WAKIX, the potential profile of our product candidates, our planned and ongoing clinical trials and expected timing of data readouts, anticipated regulatory milestones

​

​ and product launches, our future results of operations and financial position, our intellectual property, pending litigation and regulatory exclusivity, our planned leadership transition, market opportunity, business strategy, business development, products, prospective products, product approvals, and the plans and objectives of management for future operations. These statements are neither promises nor guarantees, but involve known and unknown risks, uncertainties and other important factors that may cause our actual results, performance or achievements to be materially different from any future results, performance or achievements expressed or implied by the forward-looking statements, including, but not limited to, the following: our commercialization efforts and strategy for WAKIX; the rate and degree of market acceptance and clinical utility of pitolisant in additional indications, if approved, and any other product candidates we may develop or acquire, if approved, including EPX-100, Pitolisant GR and BP-205; our research and development plans, including our plans to explore the therapeutic potential of pitolisant in additional indications; our ongoing and planned clinical trials; our ability to expand the scope of our license agreements with Bioprojet Société Civile de Recherche (“Bioprojet”); the availability of favorable insurance coverage and reimbursement for WAKIX; the timing of, and our ability to obtain, regulatory approvals for pitolisant for other indications as well as any other product candidates; our estimates regarding expenses, future revenue, capital requirements and additional financing needs; our ability to identify, acquire and integrate additional products or product candidates with significant commercial potential that are consistent with our commercial objectives; our commercialization, marketing and manufacturing capabilities and strategy; significant competition in our industry; our intellectual property position; loss or retirement of key members of management; failure to successfully execute our growth strategy, including any delays in our planned future growth; our failure to maintain effective internal controls; the impact of government laws and regulations; volatility and fluctuations in the price of our common stock; the significant costs and required management time as a result of operating as a public company; the fact that the price of Harmony's common stock may be volatile and fluctuate substantially; statements related to our intended share repurchases and repurchase timeframe; and macroeconomic effects and changes in market conditions, including the impact of tariffs, inflation and the risk of recession. These and other important factors discussed under the caption "Risk Factors" in our Annual Report on Form 10-K filed with the Securities and Exchange Commission (the "SEC") on February 24, 2026 and our other filings with the SEC could cause actual results to differ materially from those indicated by the forward-looking statements made in this press release. Any such forward-looking statements represent management's estimates as of the date of this press release. While we may elect to update such forward-looking statements at some point in the future, we disclaim any obligation to do so, even if subsequent events cause our views to change.

​

​

​

​

​

​

​

​

​

​

HARMONY BIOSCIENCES HOLDINGS, INC. AND SUBSIDIARIES

​

Earlier releases

From SEC EDGAR. Analysis by Pear Digitals from the filing alone. Not investment advice. · Latest earnings · Markdown

Screener

Plans

Premium and Pro coming soon.

Log in

New here?

Join the waitlist

Pear FMV opens to everyone soon. We'll email you when it does.